Research Analysts Set Expectations for ARCT FY2025 Earnings

Key Points

• Investment analysts at Cantor Fitzgerald have increased their FY2025 earnings per share (EPS) estimate for Arcturus Therapeutics from ($3.10) to ($3.02).
• Arcturus Therapeutics reported a quarterly EPS of ($0.34), outperforming the consensus estimate of ($1.11) by $0.77, with revenue of $28.30 million against an expectation of $17.64 million.
• The stock currently has an average rating of "Moderate Buy" with a consensus target price of $50.00, following various analyst ratings adjustments.

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) - Investment analysts at Cantor Fitzgerald boosted their FY2025 earnings per share (EPS) estimates for Arcturus Therapeutics in a note issued to investors on Tuesday, August 12th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the biotechnology company will earn ($3.02) per share for the year, up from their previous forecast of ($3.10). The consensus estimate for Arcturus Therapeutics' current full-year earnings is ($2.22) per share. Cantor Fitzgerald also issued estimates for Arcturus Therapeutics' FY2026 earnings at ($3.77) EPS.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, topping the consensus estimate of ($1.11) by $0.77. The firm had revenue of $28.30 million during the quarter, compared to the consensus estimate of $17.64 million. Arcturus Therapeutics had a negative return on equity of 24.87% and a negative net margin of 49.26%.

Several other analysts also recently commented on the company. Wells Fargo & Company lowered their price objective on Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating for the company in a research note on Tuesday. Scotiabank reissued an "outperform" rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. Wall Street Zen raised Arcturus Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, August 9th. Citigroup reaffirmed a "buy" rating and set a $49.00 price target (up from $47.00) on shares of Arcturus Therapeutics in a research report on Tuesday. Finally, Canaccord Genuity Group decreased their price target on Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating for the company in a research report on Tuesday, May 13th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $50.00.

Arcturus Therapeutics Stock Performance

Shares of Arcturus Therapeutics stock traded up $0.44 on Thursday, hitting $19.65. The company had a trading volume of 109,695 shares, compared to its average volume of 453,969. The stock has a market capitalization of $533.75 million, a price-to-earnings ratio of -8.82 and a beta of 2.26. Arcturus Therapeutics has a 1 year low of $8.04 and a 1 year high of $25.88. The stock has a 50 day moving average of $13.29 and a 200-day moving average of $13.30.

Institutional Trading of Arcturus Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ARCT. ARK Investment Management LLC increased its position in Arcturus Therapeutics by 3.9% in the first quarter. ARK Investment Management LLC now owns 2,008,480 shares of the biotechnology company's stock worth $21,270,000 after buying an additional 74,629 shares during the last quarter. Vanguard Group Inc. increased its position in Arcturus Therapeutics by 3.8% in the first quarter. Vanguard Group Inc. now owns 1,748,928 shares of the biotechnology company's stock worth $18,521,000 after buying an additional 64,367 shares during the last quarter. Schonfeld Strategic Advisors LLC increased its position in Arcturus Therapeutics by 129.7% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 849,081 shares of the biotechnology company's stock worth $14,409,000 after buying an additional 479,482 shares during the last quarter. Woodline Partners LP increased its position in Arcturus Therapeutics by 3.5% in the fourth quarter. Woodline Partners LP now owns 806,912 shares of the biotechnology company's stock worth $13,693,000 after buying an additional 26,956 shares during the last quarter. Finally, Geode Capital Management LLC increased its position in Arcturus Therapeutics by 6.4% in the second quarter. Geode Capital Management LLC now owns 606,291 shares of the biotechnology company's stock worth $7,889,000 after buying an additional 36,671 shares during the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.